<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000761967">
  <TermName>PAD regimen</TermName>
  <TermPronunciation>(... REH-jih-men)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>An abbreviation for a chemotherapy combination used to treat multiple myeloma. It includes the drugs bortezomib, doxorubicin (Adriamycin), and dexamethasone. Also called PAD.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000764481" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;PAD regimen&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000764482" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen PAD&quot;" language="es" id="_4"/>
  <SpanishTermName>régimen PAD</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Nombre de una quimioterapia combinada que se usa para el tratamiento del mieloma múltiple. Incluye los medicamentos bortezomib, doxorrubicina (Adriamycin) y dexametasona. También se llama PAD.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2014-06-12</DateFirstPublished>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000762155" url="/about-cancer/treatment/drugs/PAD">PAD</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
